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Thyroid cancer (TC) is the most common tumour of the
endocrine system. In Poland, the standardized incidence
rate in 2010 was 6.7 for women, 1.5 for men and it is char-
acterized by a constant increase. Patients with thyroid can-
cer make up a very heterogeneous group with a differential
clinical course - from an indolent to a fast progressing
which is the cause of a patient’s death.
As our studies indicate, in recent years papillary thyroid
cancer with a diameter of less than 10 mm dominates
among the cases of differentiated thyroid carcinoma
(DTC). Such situation requires the verification of the
approach to the diagnostic process - moving the diagnos-
tic burden from a palpable examination to an ultrasound
method and indicating an outbreak to cytological and
molecular examination. The open problem is reducing
the diameter of lesions displayed in ultrasonography,
which should be subjected to further assessment.
Surgical treatment with a total thyroidectomy with cen-
tral lymph node dissection is a common procedure.
Supplementary treatment with 131I has a documented
value in the cases of advanced TC. Controversy arouses
with the usage of 131I in patients with a lower stadium.
The results of ESTIMABL and HiLo studies indicate high
effectiveness of ablation with the use of an isotope with an
activity of 30mCi, regardless of endogenous or exogenous
TSH stimulation.
While monitoring the patients with DTC, the main tool
is an ultrasound examination of a neck and thyroglobulin
(TG) measurement. High hopes are connected with the
use of ultrasensitive TG measurements under exogenous
or endogenous TSH stimulation.
Isotope imaging is reserved only for patients with the
suspicion of a relapse or metastases. To examinations used
in these cases, a PET technique with the use of 124I or
FDG was joined.
Due to a very differentiated clinical course of TC, prog-
nostic indicators of worse prognoses requiring more
aggressive measures are searched for. High expectations
were connected with a BRAF mutation. Many studies have
indicated that the BRAFV600E mutation can correlate with
a more aggressive clinical course of papillary thyroid can-
cer and with a worse prognosis. The results of our studies
seem not to confirm this opinion - the high mutation fre-
quency (72.5%) in papillary thyroid cancer of very good
prognosis with a diameter of less than 10 mm.
Recent years have brought new therapeutic possibilities
for the patients with the spread of the disease and with
the lack of iodine uptake. A new group of medications
are tyrosine kinase inhibitors out of which Vandetanib
owns a registration to treat patients with medullary thyr-
oid cancer. The other agents are in the course of clinical
studies.
The most important problems for the future are: in the
field of diagnostics - the development of molecular meth-
ods which improve the accuracy of cytological diagnosis;
in the field of therapy - the identification of prognostic
indicators of a worse disease course and a more aggressive
treatment of this group of patients; seeking new medica-
tions aiming according to the pathway of oncogenesis.
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